The University of Manchester (UoM) is one of the largest single-site universities in the UK, with 40,000 students from almost every country in the world. With world-leading research and social responsibility at its heart, Manchester is a place to innovate, to lead and to make a difference. A Russell Group university, it is ranked in the top 30 universities in the world (QS World University Rankings 2019). UoM and Manchester University Foundation Trust (MFT, linked 3rd party) host the Versus Arthritis Centre for Epidemiology and the NIHR Common Disease BioResource for IMIDs. The CoInvestigators (Co-I) are part of an integrated multidisciplinary team with world-leading expertise in clinical epidemiology, digital epidemiology and neurocognitive function.
Main tasks in the project
In WP2, UoM will provide clinical insight and knowledge to contribute to the management and recruitment of rheumatic patients.
In WP6, UoM will manage recruitment for the longitudinal study to ensure recruitment targets are reached on time and within budget. We will provide data and interpretation of digital fatigue endpoints from the QUASAR study.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.